Pharmaceutical Business Review

Myasthenia Gravis Trial Shows Encouraging Results
Rare Disease Report
Some positive news for Myasthenia Gravis (MG) patients. Catalyst Pharmaceuticals has reported that their clinical trial testing Firdapse (amifampridine phosphate) in MG patients with anti-MuSK antibodies (MuSK-MG) met its primary endpoint.
Catalyst Pharma Neuromuscular Drug Succeeds (CPRX)Investopedia
Catalyst Pharmaceuticals' neuromuscular drug succeeds in seven-patient trialPharmaceutical Business Review

all 3 news articles »


Investor's Business Daily

FDA Accepts Alexion's sBLA for Generalized Myasthenia Gravis
Rare Disease Report
Some good news from Alexion for the Myasthenia Gravis (MG) community as the FDA has accepted their supplemental Biologics License Application (sBLA) to extend the indication for Soliris for the treatment of refractory generalized myasthenia gravis (gMG ...
Biotech Has $1.15 Billion In Potential Sales In Limbo On FDA OKInvestor's Business Daily
Alexion Seeks Eculizumab Approval for Ultra-Rare Neuromuscular DiseaseMonthly Prescribing Reference (registration)

all 4 news articles »


Alexion submits Soliris marketing application in Japan for ...
Seeking Alpha
Alexion Pharmaceuticals (ALXN) files a marketing application with the Japanese Ministry of Health, Labour and Welfare seeking approval of Soliris (eculizum.
Alexion Submits Application in Japan for Soliris® (Eculizumab) as a ...Business Wire (press release)

all 2 news articles »


News at OU

School of Nursing educator named national Nurse of the Year by Myasthenia Gravis Foundation of America
News at OU
“Sally's efforts to support the Myasthenia Gravis community and the Myasthenia Gravis Foundation of America over the years have been noticed and are greatly appreciated,” according to an email from Kathleen Brown, MGFA National Program Director.



TRA

Catalyst Pharma's Firdapse shows treatment effect in certain patients with myasthenia gravis; shares jump 14%
Seeking Alpha
Catalyst Pharmaceuticals (CPRX +13.7%) perks up on almost a 5x surge in volume in response to its announcement of positive top-line results from an investigator-sponsored study in Italy assessing Firdapse (amifampridine phosphate) for the treatment of ...
Catyalyst Pharma (CPRX) Reports Positive Top-Line Results from Investigator-Sponsored Trial of Firdapse® in ...StreetInsider.com
What's The Catalyst Driving CPRX?RTT News
Catalyst Pharmaceuticals (NASDAQ:CPRX) experimental drug for myasthenia gravis met main goals of studyBenchmark Monitor
Proactive Investors USA & Canada -GlobeNewswire (press release) -Market Exclusive
all 92 news articles »


Global Myasthenia Gravis Drugs Market 2017-2021 - PR Newswire
PR Newswire (press release)
Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease.

and more »


2017 Myasthenia Gravis Industry Survey, Market Size, Competitive Trends and Forecasts : Orbis Research
Medgadget (blog)
Myasthenia Gravis – Pipeline Review, H1 2017, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape. Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles ...



Myasthenia Gravis Therapeutic Pipeline Market Review, H2 2017
Medgadget (blog)
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking ...

and more »


Pharmaceutical Processing

FDA Accepts sBLA Filing of Alexion's Soliris for Rare Myasthenia ...
Pharmaceutical Processing
FDA accepts sBLA filing of Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG).
Alexion's sBLA for Soliris Receives FDA Acknowledgement - NasdaqNasdaq

all 2 news articles »


Alexion Pharma (ALXN) Says FDA Accepts sBLA Filing of Soliris to Treat Refractory Generalized Myasthenia Gravis
StreetInsider.com
Refractory generalized myasthenia gravis (gMG) patients who are anti-acetylcholine receptor (AChR) antibody-positive represent an ultra-rare segment of patients with MG—a chronic, debilitating and progressive autoimmune neuromuscular disease where ...

and more »

Google News